3-(3-fluoro-4-methoxyphenyl)-5-[2-(2-fluorophenyl)-2H-pyrazol-3-yl]benzo[c]isoxazole | 1539280-80-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-(3-fluoro-4-methoxyphenyl)-5-[2-(2-fluorophenyl)-2H-pyrazol-3-yl]benzo[c]isoxazole
• 英文别名: 3-(3-Fluoro-4-methoxyphenyl)-5-[2-(2-fluorophenyl)pyrazol-3-yl]-2,1-benzoxazole
• CAS: 1539280-80-2
• 化学式: C₂₃H₁₅F₂N₃O₂
• 分子量: 403.388
• InChiKey: HWXGNJQREHOOPS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.04
• 拓扑面积：
  53.1
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• BENZISOXAZOLES
  申请人：Hoffmann-La Roche Inc.

  公开号：US20150259334A1

  公开（公告）日：2015-09-17

  The present invention relates to compounds of general formula wherein Ar 1 /Ar 2 are phenyl or a 5 or 6-membered heteroaryl; R 1 /R 2 is hydrogen, halogen, lower alkyl, CF 3 or lower alkoxy; n,m are 1 or 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof, with the exception of the compound 2,1-benzisoxazole, 3-(4-chlorophenyl)-5-(1-phenyl-1H-pyrazol-5 -yl)-. The compounds may be used for the treatment of schizophrenia, obsessive-compulsive personality disorder, major depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, mild cognitive impairment, chemotherapy-induced cognitive dysfunction, Down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of neuro-active drugs, such as alcohol, opiates, methamphetamine, phencyclidine and cocaine.

  本发明涉及一般式为的化合物 其中Ar1/Ar2是苯基或5或6成员杂环基；R1/R2是氢、卤素、低碳基、CF3或低烷氧基；n，m为1或2；或其药学上可接受的酸盐、外消旋体混合物或其相应的对映异构体，但不包括化合物2,1-苯并异噁唑，3-(4-氯苯基)-5-(1-苯基-1H-吡唑-5-基)-。这些化合物可用于治疗精神分裂症、强迫性人格障碍、重度抑郁症、双相情感障碍、焦虑症、正常衰老、癫痫、视网膜退化、创伤性脑损伤、脊髓损伤、创伤后应激障碍、惊恐障碍、帕金森病、痴呆症、阿尔茨海默病、轻度认知障碍、化疗引起的认知功能障碍、唐氏综合症、自闭症谱系障碍、听力损失、耳鸣、脊髓小脑性共济失调、肌萎缩性侧索硬化症、多发性硬化症、亨廷顿病、中风、放射治疗、慢性应激、神经活性药物滥用，如酒精、鸦片类、甲基苯丙胺、邻-二氯苯基环已酮和可卡因。
• BENZISOXAZOLE MODULATORS OF NEUROGENESIS
  申请人：F.Hoffmann-La Roche AG

  公开号：EP2877466B1

  公开（公告）日：2016-07-06
• US9440962B2
  申请人：——

  公开号：US9440962B2

  公开（公告）日：2016-09-13